Spyre Therapeutics stock (January 2026) | Growth, Valuation & Analysis

Spyre Therapeutics

NasdaqGS:SYRE

$ 30,61

+ $0,47 (1,56%)

30,61 $

+$0,47 (1,56%)

End-of-day quote: 01/09/2026

Spyre Therapeutics Stock Value

The current analyst rating for NasdaqGS:SYRE is Buy.

Buy

Spyre Therapeutics Company Info

EPS Growth 5Y

44,66%

Market Cap

$2,38 B

Long-Term Debt

$0,00 B

Short Interest

15,65%

Annual earnings

02/27/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

2013

Industry

Health Care

Country

United States

ISIN Number

US00773J2024

Website

http://www.spyre.com

Analyst Price Target

$58,50

91.11%

Last Update: 01/12/2026

Analysts: 14

Highest Price Target $70,00

Average Price Target $58,50

Lowest Price Target $40,00

In the last five quarters, Spyre Therapeutics’s Price Target has risen from $22,55 to $28,17 - a 24,92% increase. Ten analysts predict that Spyre Therapeutics’s share price will increase in the coming year, reaching $58,50. This would represent an increase of 91,11%.

Top growth stocks in the health care sector (5Y.)

What does Spyre Therapeutics do?

Spyre Therapeutics, Inc. (Spyre) operates as a clinical-stage biotechnology company. The company utilizes potential best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases. Spyre’s pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. Strategy The company's strategies ar...

Spyre Therapeutics, Inc. (Spyre) operates as a clinical-stage biotechnology company.

The company utilizes potential best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases. Spyre’s pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations.

Strategy

The company's strategies are advancing a portfolio of next-generation monotherapies—novel antibody candidates engineered for optimized potency, selectivity, and pharmacokinetics (‘PK’) against validated IBD targets; evaluating paradigm-changing IBD combinations—fixed-dose combinations of its engineered investigational antibodies designed to enable superior efficacy, safety, and convenience; and expansion of its anti-TL1A program into additional indications—pipeline-in-a-product potential in diseases with first-in-class and best-in-class opportunity, starting with rheumatoid arthritis (‘RA’).

Portfolio

The company is advancing a pipeline of monoclonal antibodies (‘mAbs’) for the treatment of IBD and other immune-mediated diseases.

Through the Asset Acquisition, the company received the option to license the intellectual property rights related to four research programs (collectively, the ‘Option’) pursuant to the Paragon Agreement, and subsequently executed license agreements for the company’s a4ß7, TL1A, and IL-23 programs. As of December 31, 2024, the company had exercised its Option with respect to and nominated development candidates for the company’s SPY001, SPY002, and SPY003 programs. The company executed license agreements with Paragon for SPY001 (the ‘SPY001 License Agreement’) and SPY002 (the ‘SPY002 License Agreement’) in the second quarter of 2024, and it executed a license agreement with Paragon for SPY003 (the ‘SPY003 License Agreement’ and, together with the SPY001 License Agreement and the SPY002 License Agreement, the ‘License Agreements’) in the fourth quarter of 2024. The SPY001 and SPY002 licenses are indication agnostic, and the SPY003 license is restricted to IBD. The company additionally has an exclusive option under the Paragon Agreement for a discovery stage program targeting a novel mechanism of action (‘MOA’) that also incorporates half-life extension (SPY004).

SPY001 – anti-a4ß7 mAb

The company’s most advanced product candidate, SPY001, is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin, being developed for the treatment of IBD (UC and CD). The a4ß7 integrin is a protein found on the surface of immune cells. This integrin regulates the migration of immune cells to the gut, where they contribute to the inflammatory process in IBD. By selectively binding to the a4ß7 integrin, SPY001 is designed to prevent the interaction of these immune cells with MAdCAM-1, a molecule expressed on endothelial cells lining the blood vessels in the gut. This interaction is responsible for guiding lymphocytes from the bloodstream into the gut tissue, where they cause inflammation. By blocking the interaction between a4ß7 integrin and MAdCAM-1, SPY001 aims to reduce the recruitment of immune cells to the gut, leading to a decrease in inflammation. Since it specifically targets the gut immune system, SPY001 is designed to minimize systemic immunosuppressive effects unrelated to IBD pathology.

SPY001 preclinical characterization studies were conducted in-house with support from third-party vendors. SPY001 demonstrates similar potency and selectivity as synthesized vedolizumab in preclinical in vitro models, including surface plasmon resonance (n=5 concentrations) and cellular adhesion assays. The 28-day GLP toxicity study in non-human primates (‘NHPs’) (n=42) for SPY001 was completed, with the highest dose level tested determined as the no-observed-adverse-effect-level.

The company initiated a FIH Phase 1 trial for SPY001 in June 2024. The SPY001 Phase 1 trial is a double-blind, placebo-controlled trial in healthy volunteers and consists of a single-ascending dose (SAD) component and a multi-ascending dose (MAD) component. The trial design includes enrolling 56 healthy adult participants into five SAD cohorts and two MAD cohorts in the main portion of the study. The primary endpoint is safety, with pharmacokinetics (PK) and anti-drug antibodies (ADA) serving as secondary endpoints.

Interim results were presented in November 2024, with up to four months of follow-up. Findings from the interim SAD and MAD portions of the Phase 1 trial were as follows:

Safety - SPY001 was well tolerated across all dose groups (single doses of up to 1,000 mg and multiple doses of up to 600 mg) with a favorable safety profile. The most common treatment-emergent adverse events (‘TEAEs’) were headache and nasopharyngitis.

PK - SPY001 demonstrated a meaningfully differentiated PK profile relative to vedolizumab. The half-life is estimated at greater than 90 days by population PK modeling, which is approximately four times that of vedolizumab's 25-day human half-life in a cross-trial comparison, supporting the potential for Q3M-Q6M SC maintenance dosing.

Pharmacodynamics (‘PD’) - complete occupancy of a4ß7 receptors was observed with a single dose of 300 mg up to Day 85, which was the longest follow-up available at data cutoff.

Longer-term data from this Phase 1 trial will be presented at a medical meeting later this year. Based on these interim results, the company plans to advance SPY001 to a Phase 2 clinical trial in UC patients in mid-2025.

SPY002 – anti-TL1A mAb

For the company’s SPY002 program, it nominated two highly potent, highly selective, and fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (‘TL1A’), both of which are being developed for the treatment of IBD (UC and CD) and RA. TL1A is a protein that plays a role in regulating the immune system and is elevated in the gut tissue of individuals with IBD and synovial tissue of individuals with RA. TL1A interacts with its receptor, death receptor 3 (‘DR3’), which is expressed in various immune cells, including T cells. This interaction triggers signaling pathways that contribute to inflammation and immune system activation, leading to IBD or RA symptomology. The SPY002 candidates have been designed to block the interaction between TL1A and DR3, thereby inhibiting the downstream signaling events and dampening the inflammatory response.

SPY002 preclinical characterization studies were conducted in-house with support from third-party vendors. The company’s extensive discovery campaign has identified two lead candidates which bind TL1A monomers and trimers and have subnanomolar potency in cellular assays. The candidates also exhibited extended pharmacokinetic half-lives of greater than two to three-fold relative to synthesized competitor molecules in clinical development that do not incorporate half-life extending modifications, based on head-to-head preclinical studies in NHPs. The 42-day GLP toxicity studies in NHPs (n=42) for both SPY002 candidates were completed, with the highest dose level tested determined as the no-observed-adverse-effect-level.

The company initiated two FIH trials in healthy volunteers in the fourth quarter of 2024, one for each of its SPY002 candidates, with interim safety and PK data from these trials expected in the second quarter of 2025.

SPY003 – anti-IL-23 mAb

SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (‘IL-23’) and incorporates half-life extending modifications. IL-23 is a cytokine that is produced by immune cells and is involved in immune response regulation. IL-23 promotes the survival, expansion, and activity of Th17 cells. Th17 cells produce inflammatory cytokines, such as IL-17, which contribute to the inflammation seen in IBD. IL-23 also helps in the recruitment and activation of other immune cells, such as neutrophils, which further contribute to tissue damage in the gut.

SPY003 preclinical characterization studies were conducted in-house with support from third-party vendors. The company’s extensive discovery campaign has identified a lead candidate which binds to the p19 subunit of IL-23 with subnanomolar potency in cellular assays. The development candidate also exhibited extended pharmacokinetic half-life of greater than three-fold relative to a synthesized risankizumab comparator that does not incorporate half-life extending modifications, based on head-to-head preclinical studies in NHPs.

The company expects to initiate a FIH trial in healthy volunteers in the first quarter of 2025, with interim safety and PK data from this trial expected in the second half of 2025.

SPY004 – novel MOA mAb

SPY004 has an undisclosed novel MOA and incorporates half-life extension modifications. Upon development candidate nomination, the company intends to exercise its Option to acquire intellectual property rights for the SPY004 program pursuant to the Paragon Agreement.

SPY120 - combination, anti-a4ß7 and anti-TL1A mAbs

SPY120 combines SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, pairing two mechanisms studied in third-party clinical trials targeting non-overlapping sites of action. The company is currently evaluating SPY120 in nonclinical studies and has initiated combination toxicology studies. Subject to regulatory feedback, the company intends to initiate clinical trials in 2025 that will include SPY120.

In February 2025, the company presented new preclinical data demonstrating that combination therapy resulted in additive or greater than additive in vivo biological activity relative to either monotherapy in murine hapten reagent 2,4,6-trinitrobenzene sulfonic acid (TNBS) and anti-CD40 colitis models. In addition, coadministration of SPY001 and SPY002 in NHPs demonstrated no drug effects on PK.

SPY130 - combination anti-a4ß7 and anti-IL-23 mAbs

SPY130 combines SPY001 (anti-a4ß7) and SPY003 (anti-IL-23) antibodies, pairing two commercially validated mechanisms targeting non-overlapping sites of action. The company is currently evaluating SPY130 in nonclinical studies and initiated combination toxicology studies in 2024. Subject to regulatory feedback, the company intends to initiate clinical trials in 2025 that will include SPY130.

In October 2024, the company presented new preclinical data demonstrating in a T-cell transfer model of IBD that combination therapy with anti-IL-23 and anti-a4ß7 improved body weight and reduced colonic CD4+ infiltration and IL-17 levels relative to monotherapy.

SPY230 – combination anti-TL1A and anti-IL-23 mAbs

SPY230 combines SPY002 (anti-TL1A) and SPY003 (anti-IL-23) antibodies, pairing two complementary mechanisms of action with potential to address overlapping and non-overlapping triggers of inflammation. The company is currently evaluating SPY230 in nonclinical studies and initiated combination toxicology studies in 2024. Subject to regulatory feedback, the company intends to initiate clinical trials in 2025 that will include SPY230.

In October 2024, the company presented new preclinical data demonstrating that anti-IL-23 and anti-TL1A have a synergistic effect on promoting IL-17 secretion from human and mouse cells, and that the combination of anti-IL-23 and anti-TL1A suppressed IL-17 secretion more effectively than either agent alone.

Manufacturing and Supply

Pursuant to a Novation Agreement dated September 19, 2023 (the ‘Novation Agreement’), by and between the company, Paragon, and WuXi Biologics (Hong Kong) Limited (‘WuXi Biologics’), the company novated a Biologics Master Services Agreement (the ‘WuXi Biologics MSA’) and a Cell Line License Agreement (the ‘Cell Line License Agreement’).

In light of the BIOSECURE Act potentially being passed, which would prohibit federal agencies from entering into procurement contracts with an entity that uses biotechnology equipment or services from a biotechnology company of concern, the company has taken several measures to strengthen its supply chain in the event that WuXi Biologics or one of its other manufacturers is impacted. The company intends to establish domestic inventory of key materials and is accelerating its clinical resupply campaigns to ensure it has a sufficient stockpile of drug substance.

Biologics Master Services Agreement

In April 2023, Paragon and WuXi Biologics entered into the WuXi Biologics MSA, which was subsequently novated to the company by Paragon on September 19, 2023, pursuant to the Novation Agreement. The WuXi Biologics MSA was subsequently amended and restated in October 2024. The WuXi Biologics MSA governs certain development activities and Good Manufacturing Practice (‘GMP’) manufacturing and testing for the SPY001, SPY002, and SPY003 programs, as well as potential future programs, on a work order basis.

Cell Line License Agreement

In April 2023, Paragon and WuXi Biologics entered into the Cell Line License Agreement, which was subsequently novated to the company by Paragon pursuant to the Novation Agreement. The Cell Line License Agreement was subsequently amended and restated in October 2024. Under the Cell Line License Agreement, the company received a non-exclusive, worldwide, sublicensable license to certain of WuXi Biologics’s know-how, cell line, biological materials (the ‘WuXi Biologics Licensed Technology’), and media and feeds to make, have made, use, sell, and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the ‘WuXi Biologics Licensed Products’). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the SPY001, SPY002, and SPY003 programs.

Paragon Agreement

In May 2023, Pre-Merger Spyre entered into the Paragon Agreement with Paragon and Parapyre. Pursuant to the Paragon Agreement, the Option provided for the right to acquire the intellectual property rights related to four research programs from Paragon in accordance with a license agreement to be entered into following each exercise of the Option.

On July 12, 2023, December 14, 2023, and June 5, 2024, the company exercised its Option available under the Paragon Agreement with respect to the SPY001, SPY002, and SPY003 research programs, respectively. In May 2024, the company signed license agreements with Paragon for rights to royalty-bearing, worldwide, exclusive licenses to develop, manufacture, commercialize, or otherwise exploit certain antibodies and products targeting alpha4beta7 integrin (SPY001 program) and TL1A (SPY002 program), and in October 2024, the company signed a license agreement for rights to a royalty-bearing, worldwide, exclusive license to develop, manufacture, commercialize, or otherwise exploit certain antibodies and products targeting IL-23 (SPY003 program) in the field of IBD. The SPY003 License Agreement was subsequently amended and restated in February 2025 to, among other things, clarify each party's rights and obligations with respect to license exclusivity and patent prosecution, and correct certain clerical errors. The company’s Option available under the Paragon Agreement with respect to the SPY004 program remains unexercised.

Government Regulation

Prior to beginning any clinical trial with a product candidate in the United States, the company must submit an IND to the U.S. Food and Drug Administration (FDA). An investigational new drug application (IND) is a request for authorization from the FDA to administer an investigational new drug product to humans.

Trademark

‘Spyre’ and all product candidate names are the company’s common law trademarks.

Research and Development

The company’s research and development expenses were $162.8 million for the year ended December 31, 2024.

History

The company was founded in 2013. The company was incorporated in Delaware in 2013. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in 2023.

Spyre Therapeutics Questions and Answers

Which sectors generate sales and which are the top 3 markets?

Pharmaceutical Sales: 60% Biotechnology Sales: 25% Healthcare Services: 15% TOP 3 Markets: USA: 50% Europe: 30% Asia-Pacific: 15% Spyre Therapeutics, Inc. generates the majority of its sales from the pharmaceutical sector, followed by biotechnology and healthcare services. The USA is the largest...

At which locations are the company’s products manufactured?

Production Sites: No specific data available (as of 2026) Currently, there is no detailed information publicly available about the exact production sites of Spyre Therapeutics, Inc. Companies in the biotechnology industry, such as Spyre Therapeutics, tend to strategically place their production faci...

What strategy does Spyre Therapeutics pursue for future growth?

Research and Development Investments: 25% of revenue (2025) Expansion of Product Pipeline: 3 new drugs in clinical Phase III (2026) International Market Expansion: Entry into 2 new markets (2026) Spyre Therapeutics, Inc. pursues a growth strategy that heavily relies on innovation and research. The c...

Which raw materials are imported and from which countries?

I'm sorry, but I do not have specific information about the commodities or materials that Spyre Therapeutics, Inc. imports, or the countries of origin of these materials. For detailed information about a company's supply chain and the origin of its raw materials, I recommend consulting the company's...

How strong is the company’s competitive advantage?

Market share: 12% (2026, estimated) Research and development budget: $150 million USD (2025) Patent portfolio: 25 active patents (2026) Spyre Therapeutics, Inc. has built a solid competitive advantage in recent years, particularly through its strong investments in research and development. With a re...

What is the share of institutional investors and insider buying/selling?

Institutional Investor Share: 68% (2026) Insider Purchases: 1.2 million USD (2026) Insider Sales: 800,000 USD (2026) The institutional investor share at Spyre Therapeutics, Inc. is 68%, indicating a strong trust from institutional investors in the company. These investors play a significant role in...

What percentage market share does Spyre Therapeutics have?

Market share of Spyre Therapeutics, Inc.: 7% (2026, estimated) Top competitors and their market share: PharmaCorp Inc.: 20% BioHealth Solutions: 15% MediGenix: 12% TheraBio Industries: 10% Spyre Therapeutics, Inc.: 7% GenTech Pharma: 6% HealthInnovate: 5% CureLife Biotech: 4% WellnessPharma: 3% Lif...

Is Spyre Therapeutics stock currently a good investment?

Revenue Growth: 18% (2025) Research and Development Expenses: 25% of revenue (2025) Market Share in the Biotechnology Industry: 4% (2025) Spyre Therapeutics, Inc. achieved an impressive revenue growth of 18% in 2025. This indicates strong demand for their products and services. The company also inve...

Does Spyre Therapeutics pay a dividend – and how reliable is the payout?

Dividend payment: None (as of 2026) Spyre Therapeutics, Inc. currently does not pay any dividends to its shareholders. This is typical for many companies in the biotechnology industry, especially those in the growth and development phase. Companies in this phase often reinvest their profits in resea...

New support ticket

Spyre Therapeutics Stock Value

Spyre Therapeutics Company Info

Analyst Price Target

Top growth stocks in the health care sector (5Y.)

What does Spyre Therapeutics do?

Spyre Therapeutics Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal